The Technical Analyst
Avenue Therapeutics Inc [ATXI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Avenue Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.37% $0.135
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.96 mill |
| EPS: | -0.980 |
| P/E: | -0.140 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 44.26 mill |
| Avg Daily Volume: | 1.605 mill |
| RATING 2024-04-18 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.140 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.140 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.168 (25.07%) $0.0337 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.120 - 0.150 ( +/- 11.14%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-16 | Fortress Biotech, Inc. | Buy | 413 507 | COMMON STOCK, PAR VALUE $0.0001 |
| 2024-01-02 | Fortress Biotech, Inc. | Buy | 2 101 496 | COMMON STOCK, PAR VALUE $0.0001 |
| 2023-12-11 | Davidow Robert L | Sell | 264 000 | Common Stock |
| 2023-12-11 | Davidow Robert L | Sell | 126 000 | Common Stock |
| 2023-12-11 | Davidow Robert L | Sell | 128 000 | Common Stock |
| INSIDER POWER |
|---|
| 72.53 |
| Last 83 transactions |
| Buy: 6 766 707 | Sell: 1 021 576 |
Forecast:
16:00 - $0.135
Live Trading Signals (every 1 min)
Forecast
1: 15:53 - $0.134
Forecast 2: 16:00 - $0.135
Forecast 3: 16:00 - $0.135
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.135 (-0.37% ) |
| Volume | 0.290 mill |
| Avg. Vol. | 1.605 mill |
| % of Avg. Vol | 18.06 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATXI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Latest Press Releases
2024-03-25 08:30:00 - Press Release
Avenue Therapeutics To Host Virtual Key Opinion Leader (kol) Event On April 4, 2024
Miami, march 25, 2024 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“kol”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“sbma”), also known as kennedy's disease, on thursday, april 4, 2024 at 11:00am et.
2024-03-18 16:05:00 - Press Release
Avenue Therapeutics Reports Full Year 2023 Financial Results And Recent Corporate Highlights
- enrollment completed in phase 1b/2a clinical trial of aj201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 -
2024-03-15 08:15:00 - Press Release
Avenue Therapeutics Receives Positive Listing Determination From Nasdaq
Miami, march 15, 2024 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated march 11, 2024, the nasdaq hearings panel granted the company's request for an extension to evidence compliance with all applicable criteria for continued listing on the nasdaq capital market, including the $1.00 bid price and $2.5 million stockholders' equity requirements, through may 20, 2024. the company is considering all available options that may enable it to timely evidence compliance with the continued listing criteria and maintain its listing on nasdaq; however, there can be no assurance that the company will be able to do so.
2024-03-11 08:00:00 - Press Release
Avenue Therapeutics To Present Baer-101 Preclinical Data At American Society For Experimental Neurotherapeutics (asent) 2024 Annual Meeting
Baer-101 demonstrated full suppression of seizure activity in synapcell's gaers model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans
2024-02-22 08:30:00 - Press Release
Avenue Therapeutics Announces Publication In Drug Development Research Highlighting First-in-class Preclinical Data Of Baer-101 In A Translational Model Of Absence Epilepsy
-in vivo data supports baer-101's unique ability to significantly suppress seizures using the synapcell's genetic absence epilepsy rat from strasbourg (“gaers”) model of absence epilepsy- -in vivo data supports baer-101's unique ability to significantly suppress seizures using the synapcell's genetic absence epilepsy rat from strasbourg (“gaers”) model of absence epilepsy-
Latest News
2024-03-11 08:00:00 - GlobeNewsWire
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans
2023-12-01 08:30:00 - GlobeNewsWire
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.
2023-11-29 08:05:49 - InvestorPlace
Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?
Avenue Therapeutics (NASDAQ: ATXI ) stock is rising higher after the company revealed a major investment from Robert Davidow. According to a filing with the Securities and Exchange Commission (SEC), Davidow now holds a 14.5% stake in the specialty pharmaceutical company.
2023-09-05 08:30:00 - GlobeNewsWire
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference scheduled to take place September 11-13, 2023. The presentation will be available for on-demand viewing starting Monday, September 11, 2023 at 7:00 a.m. ET.
2023-04-27 08:30:00 - GlobeNewsWire
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
MIAMI, April 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the Aegis Capital Virtual Conference taking place on Thursday, May 4, 2023, at 4:00 p.m. EDT.
2022-10-17 19:41:22 - 24/7 Wall Street
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
2022-10-16 11:30:00 - PennyStocks
New to Trading Penny Stocks? Must Knows in 2022
Are these methods part of your penny stocks trading strategy The post New to Trading Penny Stocks? Must Knows in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-10-07 09:21:59 - Benzinga
What In The World Is Going On With Avenue Therapeutics Stock?
Avenue Therapeutics Inc (NASDAQ: ATXI) shares are trading lower by 62.64% to $2.35 Friday morning after the company priced a roughly 3.6 million unit offering at $3.30 per unit.
2022-09-27 13:40:18 - InvestorPlace
ATXI Stock Alert: What to Know as Avenue Therapeutics Soars 150%
It's been another bumpy day in the stock market, with many stocks opening higher only to lose momentum this afternoon. That said, some companies are outperforming meaningfully today.
2022-09-23 10:49:21 - InvestorPlace
What Is Going on With Avenue Therapeutics (ATXI) Stock Today?
Source: Numstocker/Shutterstock.com Avenue Therapeutics (NASDAQ: ATXI ) stock is seeing wild movement on Friday following a reverse stock split and regulatory update. Starting with that reverse stock split, the company consolidated 15 shares of ATXI stock into a single share.